Jefferson University Hospitals

Provider Profile

Thomas P. Leist, MD

Jefferson University Physician

Academic Title: Professor
Director, Comprehensive Multiple Sclerosis Center

Neurology - Neuroimmunology

Make An Appointment

Click to call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

909 Walnut Street
2nd Floor, COB Bldg.
Philadelphia PA 19107
Phone: (215) 955-6871
Fax: (215) 503-2990

Medical Services

Years in Practice


Board Certifications

  • Neurology

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital

Awards and Honors

Philadelphia Magazine's Top Docs 2016,2015


Dr. Leist is a neurologist who specializes in the care of patients with multiple sclerosis. He only sees patients who have been referred by another neurologist.


  • University of Miami School of Medicine, Medical School


  • University of Miami Hospitals & Clinic


  • Weill Cornell Medical Center - New York Presbyterian Hospital


  • National Institute of Health

Jefferson physicians accept most health insurance plans, including those listed below. However, plan acceptance may vary by practice and may be subject to change. If you have questions about whether a specific physician accepts your insurance, please contact your insurance company.

Insurances Accepted

  • Aetna
  • Aetna PA Employee Benefit Trust Fund (PEBTF)
  • AmeriHealth
  • AmeriHealth Comprehensive
  • AmeriHealth HMO
  • AmeriHealth Personal Choice
  • Blue Cross/Blue Shield
  • Cigna Healthspring
  • Cigna PPO, POS
  • Consumer Health Network PPO
  • CorVel
  • Devon
  • Employers Health Network PPO
  • Evolutions (Guardian Resources)
  • Federal BCBS
  • Geisinger Health Plan
  • Health America PPO
  • Health Management Network PPO
  • Horizon Blue Cross/Blue Shield
  • HumanaChoicePPO,Medicare,GoldPlusHMO
  • Jeff Plus
  • Keystone 65 HMO
  • Keystone First VIP Choice
  • Keystone Health Plan East
  • Medicare
  • Mercy LIFE
  • MultiPlan Inc.
  • NJ Plus
  • Personal Choice (GPPPN)
  • Personal Choice 65
  • PlanCare America
  • Preferred Care PPO
  • Premier Blue
  • Prime Health Services, Inc.
  • Qualcare
  • Tricare
  • United Healthcare
  • UPMC HMO,PPO ReadingHspEmpONLY
  • UPMC Medicare HMO
  • US Family Health Plan


Recent Publications

Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis

Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions

Therapy Optimization in Multiple Sclerosis: A cohort study of therapy adherence and risk of relapse

Expression of GM-CSF in T cells is increased in multiple sclerosis and suppressed by IFN-β therapy

Therapy optimization in multiple sclerosis: A prospective observational study of therapy compliance and outcomes

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): A phase 3 randomised trial

Relevance of MOA in MS treatment efficacy

Novel Therapeutics in Multiple Sclerosis Management: Clinical Applications

Case scenario #2

Case scenario #1

Multitasking in multiple sclerosis: Can it inform vocational functioning?

Cladribine: Mode of action and implications for treatment of multiple sclerosis

Magnetic resonance imaging and treatment effects of multiple sclerosis therapeutics

Human optic nerve DTI with EPI geometric distortion correction

Thickness of retinal nerve fiber layer correlates with disease duration in parallel with corticospinal tract dysfunction in untreated multiple sclerosis

Toward a practical protocol for human optic nerve DTI with EPI geometric distortion correction

When metals compete: A case of copper-deficiency myeloneuropathy and anemia

Phase Labeling Using Sensitivity encoding (PLUS): Data acquisition and image reconstruction for geometric distortion correction in EPI

Geometric distortion correction in EPI by phase labeling using sensitivity encoding (PLUS)

Multiple sclerosis risk after optic neuritis: Final optic neuritis treatment trial follow-up